ATAT1 and hematoma: These findings suggest that MEC17 and α-Ac-Tub deficiencies in ECs exacerbate BBB injury, brain edema, inflammation, hematoma volume and motor dysfunction after ICH, highlighting their potential as therapeutic targets for BBB protection.